Chinasupplierof35189-28-7NorgestimateSynonyms:D-(17A)-17-Acetoxy-13-ethyl-18,19-dinorpregn-4-en-20-yn-3-oneoxime;Norgestimatepowder;NorgestimatesteroidCAS:35189-28-7Formula:C23H31NO3MolecularWeight:369.50Density:1.221g/cm3MeltingPoint:216°CBoilingPoint:497.896°Cat760mmHgFlashPoint:254.919°CAppearance:WhitecrystallinesolidPurity:98%PackAge:AccordingtotheclientsrequirementApplication:ItisanimportantrawmaterialStorage:Storeindry,darkandventilatedplace.Description:Norgestimateisaformofprogestin,whichisafemalehormoneimportantfortheregulationofovulationandmenstruation.Norgestimateisusedwithestradiol(afemalesexhormonethatisinvolvedinthedevelopmentandmaintenanceofthefemalereproductivesystem),totreatthesymptomsofmenopause.Norgestimateandethinylestradiolareusedasanoralcontraceptive,indicatedforthepreventionofpregnancyinwomen.Application:Norgestimate/ethinylestradiolisindicatedforthepreventionofpregnancyinwomenwhoelecttouseoralcontraceptivesasamethodofcontraception.Mifepristoneisusedfor:Endingpregnancyinwomenwhoh***ebeenpregnantfor49days(7weeks)orless.Itmaybeusedwithothermedicines.Ifmifepristonedoesnotwork,surgerytoendthepregnancymaybenecessary.Mifepristoneisasyntheticsteroide.Itworksbyblockingahormone(progesterone)necessaryforpregnancytocontinue.Howtousemifepristone:Usemifepristoneasdirectedbyyourdoctor.Checkthelabelonthemedicineforexactdosinginstructi***.MifepristonecomeswithanextrapatientinformationsheetcalledaMedicationGuideandaPatientAgreement.Readthemcarefully.Readthemagaineachtimeyougetmifepristonerefilled.Mifepristoneissuppliedbyyourhealthcareproviderandisnot***ailableatapharmacy.Mifepristonerequires3visitstoyourhealthcareprovider.Onday1atyourhealthcareprovider'soffice,youwillreadtheMedicationGuideanddiscussthebenefitsandrisksofusingmifepristonetoendyourpregnancy.Ifyoudecidemifepristoneisrightforyou,signthePatientAgreement.Afteryourphysicalexam,youwilltake3tabletsofmifepristone.Onday3atyourhealthcareprovider'soffice,ifyouarestillpregnant,youwilltake2misoprostoltablets.Misoprostolmaycausecramps,nausea,diarrhea,andothersymptoms.Yourhealthcareprovidermaygiveyouothermedicinesforthesesymptoms.Aroundday14atyourhealthcareprovider'soffice,youwillreturnforanimportantfollow-upvisit.Youmustreturnabout14daysafteryouh***etakenmifepristonetobesurethepregnancyhasended.Ifthepregnancyhasnotended,thereisachanceofbirthdefects.Yourhealthcareproviderwilldiscusswithyouyourchoices,includingsurgicalabortion.Grapefruitandgrapefruitjuicemayincreasetheriskofsideeffectsfrommifepristone.Talktoyourdoctorbeforeincludinggrapefruitorgrapefruitjuiceinyourdietwhiletakingmifepristone.Youmustfollowthedosingscheduleasdirectedbyyourdoctor.Ifyoumissanappointment,contactyourdoctorimmediately.Formulati***/Preparati***:Norgestimateis***ailablecommerciallyasacomponentofacombinationtabletwithethinylestradiol.Drugwarning:(1)Cigarette***okingincreasestheriskofseriouscardiovascularsideeffectsfromoralcontraceptiveuse.Thisriskincreaseswithageandwithhe***y***oking(15ormorecigarettesperday)andisquitemarkedinwomenover35yearsofage.Womenwhouseoralcontraceptivesshouldbestronglyadvisednotto***oke.(2)Oralcontraceptivesshouldnotbeusedinwomenwhocurrentlyh***ethefollowingconditi***:thrombophlebitisorthromboembolicdisorders;apasthistoryofdeepveinthrombophlebitisorthromboembolicdisorders;cerebralvascularorcoronaryarterydisease(currentorpasthistory);valvularheartdiseasewithcomplicati***;severehypertension;diabeteswithvascularinvolvement;headacheswithfocalneurologicalsymptoms;majorsurgerywithprolongedimmobilization;knownorsuspectedcarcinomaofthebreastorpersonalhistoryofbreastcancer;carcinomaoftheendometriumorotherknownorsuspectedestrogen-dependentneoplasia;undiagnosedabnormalgenitalbleeding;cholestaticjaundiceofpregnancyorjaundicewithpriorpilluse;acuteorchronichepatocellulardiseasewithabnormalliverfunction;hepaticadenomasorcarcinomas;knownorsuspectedpregnancy;hypersensitivitytoanycomponentofthisproduct.(3)Theuseoforalcontraceptivesisassociatedwithincreasedrisksofseveralseriousconditi***includingmyocardialinfarction,thromboemboli***,stroke,hepaticneoplasia,andgallbladderdisease,althoughtheriskofseriousmorbidityormortalityisvery***allinhealthywomenwithoutunderlyingriskfactors.Theriskofmorbidityandmortalityincreasessignificantlyinthepresenceofotherunderlyingriskfactorssuchashypertension,hyperlipidemias,obesityanddiabetes.)